Clinical Trials Browser

NCT04840602 2026-03-18

Testing the Combination of Venetoclax and Rituximab, in Comparison to the Usual Treatment (Ibrutinib Plus Rituximab or Zanubrutinib Alone) for Waldenstrom's Macroglobulinemia/Lymphoplasmacytic Lymphoma

Phase 2 Recruiting

92 enrolled

Lymphoid

Waldenstrom Macroglobulinemia, Lymphoma, B-Cell, Marginal Zone

NCT05963074 2026-03-13

TAILOR

Phase 2 Recruiting

320 enrolled

LymphoidOther hematologic neoplasm

Leukemia, Lymphocytic, Chronic, B-Cell

NCT05283720 2026-03-03

A Study to Evaluate Adverse Events and Change in Disease Activity of Subcutaneous (SC) Epcoritamab in Combination With Oral and Intravenous Anti-Neoplastic Agents in Adult Participants With Non-Hodgkin Lymphoma

Phase 2 Recruiting

496 enrolled

LymphoidOther hematologic neoplasm

Leukemia, Hairy Cell, Lymphoma, Non-Hodgkin, Neoplasms, Recurrence, Lymphoma, Large B-Cell, Diffuse

NCT05998642 2026-02-12

Ibrutinib Combination Therapy in Transplant Ineligible Individuals With Newly Diagnosed Primary CNS Lymphoma

Phase 2 Recruiting

30 enrolled

Lymphoid

Lymphoma, Non-Hodgkin

NCT06271616 2025-12-26

Ibrutinib for the Prevention of Chronic Graft-Versus-Host Disease in Patients Undergoing Donor Stem Cell Transplant

Phase 2 Recruiting

40 enrolled

Bronchiolitis Obliterans Syndrome

NCT06958705 2025-11-25

Venetoclax as Consolidation in CLL Patients Treated With BTK Inhibitor Monotherapy

Phase 2 Recruiting

79 enrolled

LymphoidOther hematologic neoplasm

Leukemia, Lymphocytic, Chronic, B-Cell

NCT03128879 2025-11-21

Venetoclax With Ibrutinib or Acalabrutinib in Pts. With High-risk CLL

Phase 2 Recruiting

90 enrolled

LymphoidOther hematologic neoplasm

Leukemia, Lymphocytic, Chronic, B-Cell

NCT04450173 2025-04-24

Obinutuzumab, Ibrutinib, and Venetoclax for the Treatment of Previously Untreated Stage II-IV Follicular Lymphoma

Phase 2 Recruiting

40 enrolled

Lymphoid

Lymphoma, Follicular

NCT06482684 2024-07-01

CARMAN

Phase 2 Recruiting

150 enrolled

Lymphoid

Lymphoma, Mantle-Cell

NCT05694312 2023-12-01

Ibrutinib for the Treatment of AIHA in Patients With CLL/SLL or CLL-like MBL

Phase 2 Recruiting

45 enrolled

Classical hematologyLymphoidOther hematologic neoplasm

Anemia, Hemolytic, Autoimmune, Leukemia, Lymphocytic, Chronic, B-Cell

NCT04758975 2023-10-04

VALUABLE

Phase 2 Recruiting

55 enrolled

LymphoidOther hematologic neoplasm

Leukemia, Lymphocytic, Chronic, B-Cell

NCT04908228 2023-10-03

FIGHT

Phase 2 Recruiting

53 enrolled

LymphoidOther hematologic neoplasm

Leukemia, Lymphocytic, Chronic, B-Cell